Bimekizumab (Bimzelx; UCB Pharma) was approved by the FDA to treat psoriatic arthritis (PsA) on September 23, 2024, based on ...

Researchers identified 3 distinct PsA phenotype clusters, emphasizing the importance of PsO severity in treatment decision making.

DMARDs are often used to treat RA and inflammatory types of arthritis, such as ankylosing spondylitis, psoriatic arthritis ...

For patients with psoriatic arthritis, switching directly from adalimumab to tofacitinib with no washout period presents no ...

DWP has listed 87 musculoskeletal conditions being supported through PIP to help with either daily living, mobility needs or ...

Topline data were announced from two phase 3 trials evaluating deucravacitinib in adults with active psoriatic arthritis.